1629. Acceptability and Trust in the Low-dose Intradermal Mpox Vaccine: a Knowledge, Attitudes and Practices Sub-analysis of the Observational Study of Mpox Immunity (OSMI) in NYC

BACKGROUND: In the 2022 Mpox outbreak, the US FDA issued an EUA for a low-dose intradermal (ID) vaccination regimen to increase vaccine supply by five-fold. The ID regimen had yet to be evaluated for immunogenicity or tolerability in persons with HIV or for general acceptability. METHODS: We conduct...

Descripción completa

Detalles Bibliográficos
Autores principales: Carmody, Ellie, Parameswaran, Lalitha, Wilson, Kesi K, Kottkamp, Angelica C, Frank, Olivia, Engelson, Celia, Davis, Tamia S, Noriega, Irma, Callahan, Jacqueline, Yip, Samantha, Youn, Heekoung, Rettig, Stephanie, Wagner, Julia, Nweke, Samuel, Suman, Pamela, Samanovic, Marie I, Duerr, Ralf, Haiken, Sarah, Mulligan, Mark J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677249/
http://dx.doi.org/10.1093/ofid/ofad500.1463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677249/
http://dx.doi.org/10.1093/ofid/ofad500.1463

Ejemplares similares